financetom
Technology
financetom
/
Technology
/
Valens Semiconductor Q3 revenue beats; names new CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Valens Semiconductor Q3 revenue beats; names new CEO
Nov 12, 2025 3:58 AM

Overview

* Valens Q3 2025 revenue of $17.3 mln beats analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, reflecting strong operational performance

* Company appoints Yoram Salinger as new CEO, effective November 13, 2025

Outlook

* Valens expects Q4 2025 revenue between $18.2 mln and $18.9 mln

* Company anticipates full-year 2025 revenue of $69.4 mln to $70.1 mln

* Valens forecasts Q4 2025 adjusted EBITDA loss between $(4.6) mln and $(4.2) mln

Result Drivers

* CIB GROWTH - Cross-Industry Business segment revenue increased, driven by product mix changes

* PROAV DEMAND - Higher than expected customer demand in ProAV market boosted revenues

* AUTOMOTIVE MARGIN DECLINE - Automotive segment gross margin declined due to product mix and operational expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $17.34 $15.40

Revenue mln mln (4

Analysts

)

Q3 Beat -$0.04 -$0.06

Adjusted (4

EPS Analysts

)

Q3 Net -$7.32

Income mln

Q3 Beat -$4.30 -$7.15

Adjusted mln mln (2

EBITDA Analysts

)

Q3 Beat -$7.31 -$7.90

Pretax mln mln (4

Profit Analysts

)

Q3 66.70%

Adjusted

Gross

Margin

Q3 -$18.96

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the semiconductors peer group is "buy"

* Wall Street's median 12-month price target for Valens Semiconductor Ltd ( VLN ) is $4.00, about 55% above its November 11 closing price of $1.80

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings
Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings
Oct 21, 2025
The investment enhances German facility to deliver more flexible and scalable drug delivery solutions PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced a significant expansion of its drug delivery system manufacturing capacity, further strengthening its global footprint to...
European third-quarter corporate outlook worsens slightly
European third-quarter corporate outlook worsens slightly
Oct 21, 2025
By Javi West Larrañaga and Marleen Kaesebier Oct 21 (Reuters) - The outlook for European corporate health has slightly worsened, the latest earnings forecasts showed on Tuesday. European companies are expected to report an increase of 0.2% in third-quarter earnings, on average, according to LSEG I/B/E/S data, below the 0.5% growth analysts were expecting a week ago. That would be...
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
Oct 21, 2025
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics ( SION ), Inc. , a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the...
Lightbridge to Hold Business Update & Third Quarter 2025 Earnings Conference Call on Thursday, November 6 at 4 p.m. ET
Lightbridge to Hold Business Update & Third Quarter 2025 Earnings Conference Call on Thursday, November 6 at 4 p.m. ET
Oct 21, 2025
RESTON, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Lightbridge Corporation ( LTBR ) (“Lightbridge” or the “Company”) , an advanced nuclear fuel technology company, will announce its financial results for the third quarter of fiscal year 2025 on Wednesday, November 5, after the market closes. Lightbridge ( LTBR ) will host a conference call on Thursday, November 6, at 4:00...
Copyright 2023-2026 - www.financetom.com All Rights Reserved